The GenoDiabMar registry. A collaborative research platform of "real world" type 2 diabetes patients.

Authors:

Adriana Sierra¹, Sol Otero², Eva Rodríguez¹, Anna Faura¹, María Vera¹, Marta Riera¹, Vanesa Palau¹, Xavier Durán³, Anna Costa-Garrido³, Laia Sans¹, Eva Márquez¹, Vladimir Poposki⁴, Josep Franch-Nadal^{5,6}, Xavier Mundet^{5,7}, Anna Oliveras¹, Marta Crespo¹, Julio Pascual^{1,8}, Clara Barrios^{1*}.

1- Department of Nephrology, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.

2- Department of Nephrology, Consorci Sanitari Alt Penedès-Garraf, Barcelona, Spain

3- Methodological and Biostatistical Advisory Service, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.

4-Department of Ophthalmology, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.

5- Research Support Unit. University Institute for Research in Primary Care, Jordi Gol (IDIAP Jordi Gol).

6-Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Barcelona, Spain.

7- Departamento de Medicina, Universidad Autonoma de Barcelona, Bellaterra, Spain.

8- Current Position: Department of Nephrology Hospital Universitario 12 de Octubre, Madrid, Spain.

*Corresponding author.

Abstract

The GenoDiabMar registry is a prospective study aims to provide data on demographic, biochemical and clinical changes, from a “real-world” population of Type 2 DM (T2D) patients. This registry is addressed to find new biomarkers related to the micro and macrovascular complications of T2D, especially focused on diabetic nephropathy. The registry includes longitudinal serum and urine samples, DNA bank, as well as data on 227 metabolomics profiles, 77 Immunoglobulin G glycomics traits and others emerging biomarkers. 650 patients aged 69.56 ± 9.31 with different grades of chronic kidney disease; (G1-2 50.3%, G3 31.4%, G4 10.8% and G5 7.5%) were followed up for 4.96 (± 0.43) years. Regardless of albuminuria, women lost 0.93 (0.40-1.46) glomerular filtration units per year less than men. 17% of the participant experienced rapid progression of renal function, 75.2% men, with differential risk factors between sexes; severe macroalbuminuria $>300\text{mg/g}$ for men OR[IQ] 2.40 [1.29:4.44] and concomitant peripheral vascular disease 3.32 [1.10:9.57] for women. An overall mortality of 23% was detected (38% due to Cardiovascular aetiology).

This cohort is postulated as a great tool for scientific collaboration for studies, whether they are focused on T2D, or whether they are interested in comparing differential markers between diabetic and non-diabetic populations.

1. INTRODUCTION

Diabetes mellitus affects more than 450 million people in the world, reaching pandemic levels, being the type 2 diabetes (T2D) patients up to 95% of the cases (1). The main complications of diabetes, both microvascular (retinopathy, neuropathy, nephropathy) and macrovascular (ischemic cardiopathy, peripheral vascular disease, cerebrovascular disease), increase the costs associated and entail an important reduction in the quantity and the quality of patients' life (2–4).

In recent decades, the improvement in prevention strategies and therapeutic interventions has led to a significant reduction in most diabetes complications. However, this is not so evident in the case of diabetic kidney disease (DKD), that remains the leading cause of end stage renal disease (ESRD) in Western countries (5,6). When diabetes induces renal damage, patients have a higher risk of suffering from endothelial disease in any other territory of the body, and patients with DKD have the highest cardiovascular (CV) risk and mortality among patients with chronic kidney disease (CKD) (7–12). Therefore, it is essential to focus attention and effort on the early prevention, diagnosis, and treatment of DKD. Despite the high prevalence and increasing incidence of this disease, the underlying pathophysiological mechanisms are not fully understood and even currently, highly sensitive and specific diagnostic tests are not available. In this way, classical biomarkers used to estimate glomerular filtration rate (eGFR) and renal damage such as serum creatinine and albuminuria, have well-known limitations (13–18), and may fail in the early detection of kidney impairment.

In past years, high-throughput techniques have shown the feasibility of finding new biomarkers of early kidney dysfunction, as well as providing valuable information on the metabolic pathways involved in the physiopathology of DKD and other diabetic micro and macrovascular complications (19–28).

The analysis of hundreds of metabolites, protein glycosylation profiles, genetic variants or emerging biomarkers, require of large sample size cohorts to robustly detect associations. GenoDiabMar is a detailed cohort useful as a tool to improve and expand knowledge on different pathophysiological pathways involved in diabetic complications and allow to replicate results obtained in different populations to generate collaborative research

We present the GenoDiabMar registry, created with the aim of providing data on demographic, biochemical and longitudinal clinical changes, as well as, to obtain biological samples for biobank, from a population of T2D patients attending a real medical out-patient consult. Also, this registry is addressed to find new emerging biomarkers related to the micro and macrovascular complications of T2D, especially focused on diabetic nephropathy.

2. METHODS

2.1. Study design

The GenoDiabMar registry was designed as a prospective study and currently collected information regarding 650 Caucasians adults with T2D recruited from the nephrologist consultant of Hospital del Mar and six primary care centres from the Hospital del Mar health area, Litoral-Mar of Barcelona, Spain. The inclusion criteria were adults over 45 years old, diagnosed with T2D at least 10 years before the first study visit, if there was no renal disease, and at any time, if renal damage was present. Information on the diagnosis of T2D was retrieved from the patient's electronical medical records. To avoid the inclusion of patients with pre-diabetes or impaired glucose tolerance and to ensure the T2D diagnosis, only patients under antidiabetic drugs were registered.

Patients with autoimmune polycystic kidney disease or with previously known autoimmune diseases as vasculitis or systemic lupus erythematosus were excluded.

Thus, patients who agreed to participate, met the inclusion criteria, and signed the informed consent were enrolled.

Between February 2012 and July 2015, 650 T2D patients underwent a basal in-person medical visit (V1) performed by a nephrologist and a nurse. Medical history, demographics, physical examination, and laboratory data were registered along with collection of blood and urine samples. In addition, an annually follow up of all participants included at the baseline visit was performed to obtain complete analytical and clinical parameters, including new cardiovascular events, changes in the status of diabetic retinopathy and nephropathy, and in mortality, by consulting participants' electronic clinical reports.

Between March 2017 and February 2020, living patients with functioning kidneys who did not require renal replacement therapy, underwent the second in-person visit (V2). Again, analytical, and clinical data, including changes in treatments, were registered. The second biological samples for biobank were collected in this second visit, performed on an average of 4.96 (± 0.43) years from the baseline visit.

The study protocol was approved by the local Medical Ethics Committee of our research institute and the Steering Committee of the Primary Care Area. Patients were previously informed of the collection of samples for the biobank and the use of their clinical data. National guidelines (Code of ethics of the professional association) and international guidelines (Declaration of Helsinki Fortaleza, Brazil, October 2013) were followed. Also, confidentiality of the data was guaranteed in accordance with current regulations: Organic Law 3/2018, of December 5, Protection of Personal Data and guarantee of digital rights and Regulation (EU) No 2016/679 of the Parliament and Council of April 27, 2016 on Data Protection (RGPD). In addition, the study was carried out in accordance with the Biomedical Research Law (Law 14/2007). No binding data are shared for the patient and all data are pseudo-anonymized with a new coding of the medical record number and anonymous labelling of blood samples.

2.2. Data Registry

Medical records and CV risk factors assessment

Each participant completed a comprehensive questionnaire about their medical history, including information related to the presence and type of Diabetes Mellitus in the family history. Smoking status was registered as current smoker, previous smoker (smoke-free for more than 1 year) or no smoker. Body mass index (BMI) was calculated as weight/height² (Kg/m²). The history of CV events was recorded at the baseline and annually and comprised, 1- ischemic heart disease (acute myocardial infarction, angina, cardiac revascularization); 2- cerebrovascular disease (cerebrovascular accident or transient ischemic attack) and 3- peripheral vascular disease (intermittent claudication, ischemic vascular ulcers, or surgical revascularization).

Hypertension was considered if the patient had previously been diagnosed or if they were under anti-hypertensive treatment. In addition, new cases of hypertension were

identified if the patient presented systolic blood pressure (SBP) of 140 mmHg or higher, and/or diastolic blood pressure (DBP) of 90 mmHg or higher at the visit (29). Blood pressure was measured with an automatic calibrated sphygmomanometer following a standardized protocol, recording the average of three measurements separated each by 3-5 min. Also, absolute values were recorded in the dataset.

Dyslipidaemia was considered both as quantitative variable including the absolute values of the lipid profiles component, i.e., determination of total cholesterol > 250mg/dL, LDL cholesterol > 130 mg/dL, HDL cholesterol <35/45 mg/dL (men/women respectively), triglycerides >200 mg/dL (30), and as qualitative variable if previously diagnosed by a physician or the patient used of lipid-lowering medication.

The presence or absence of diabetic retinopathy (DR) is recorded as categorical variable and was diagnosed by fundoscopy performed by an ophthalmologist. It was classified as unknown retinopathy in the case of lack of fundoscopy. In addition, the presence of cataracts diagnosed in the ophthalmological examination was recorded.

The registry also gathered the medication in use at baseline and changes during the follow up, including: Anti-hypertensive drugs distinguishing inhibitors of renin-angiotensin-aldosterone system, calcium antagonists, beta-blockers, diuretics, or combinations; Lipid-lowering treatment (statins, fibrates or others such as omega3 polyunsaturated fatty acids or ezetimibe); antidiabetic drugs distinguishing insulin, all oral antidiabetic drugs, including tubular sodium glucose co-transporter inhibitors (iSGLT2) or glucagon-like peptide-1 (GLP1-RA) receptor agonists.

2.3. Laboratory Data and sample management

At baseline (V1) and at the last visits (V2), fasting venous blood and urine samples were collected. A 20 ml of EDTA (Ethylene diamine tetra acetic) blood sample was obtained from all participants. The samples were centrifuged (4000 rpm; 3 ml for 10 min at 4°C) and stored at -80°C until use. For participants undergoing renal replacement therapy with haemodialysis, fasting samples were taken before the mid-week dialysis treatment procedure. Serum, urine, DNA and whole blood samples were stored in freezers of the Nephropathies Research Group (GREN) of the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) (31) and the Parc de Salut Mar Biobank (MARBiobanc) (32). All samples

for clinical analysis were centralized in a single laboratory, the Catalan Reference Laboratory (LRC). The main variables are summarized in tables 1 and 2.

Renal function was measured as estimated glomerular filtration rate (eGFR) from calibrated serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (33). Moderate albuminuria was defined as a urine albumin-to-creatinine ratio (ACR) of 30-299 mg/g, and severe albuminuria was defined as a urine ACR of 300 mg/g or greater. DKD was defined as: eGFR<60 ml/min/1.73m² and albuminuria >300 mg/g or albuminuria 30-299 mg/g and DR, regardless the eGFR. Patients were classified based on the degree of kidney disease following the KDIGO guidelines as grade 1-2 if eGFR>90-60 ml/min/1.73m², grade 3 if eGFR; 59-30 ml/min/1.73m², grade 4 if eGFR; 29-15 ml/min/1.73m² and grade 5 if eGFR<15 ml/min/1.73m² (34).

Novel molecules and biomarkers. - Alongside with the conventional epidemiological phenotypes assessed by questionnaires, clinical visits, analytical and medical reports, the GenoDiabMar registry also benefits from high-throughput techniques to assess new biomarkers related to T2D complications.

Metabolomic profiles. - Metabolic profiling of 227 metabolic traits, 143 metabolite concentrations, 80 lipid ratios, 3 lipoprotein particle sizes and a semi-quantitative measure of albumin, were determine by Nightingale Health Ltd. (Helsinki, Finland) using a targeted NMR (nuclear magnetic resonance) spectroscopy platform that has been extensively applied for biomarker profiling as previously described (35–39). The metabolomics GenoDiabMar data has been used in a collaborative research study with other three European cohorts TwinsUK (40), KORA (41) and YoungFinns (42), that allowed us to detect metabolomic profiles associated with kidney function, and to identify similarities and discordances between diabetic and non-diabetic populations (26). The registry has metabolomic data from both, the initial and final follow-up visit samples. This may help to assess not only the prognostic value of different metabolic profiles on kidney function and other diabetes complications, but also to rule out the fortuity or causality of the findings.

Immunoglobulin G (IgG) glycans analysis. - Glycosylation is the most abundant and diverse form of the post-translational modifications of the proteins. Glycans not only play a structural, but also an important functional and regulatory role, and participates

in most physiologic process. Immunoglobulin G (IgG) is involved in infectious, autoimmune and inflammatory processes (43–46). Variations in its glycans structures influence the effector function of IgG, modulating its immune response as pro-inflammatory or anti-inflammatory. IgG glycans have been associated with a high variety of conditions, including CKD (27,47). All the GenoDiabMar participants have 76 IgG glycans profiles analysed by high performance liquid chromatography (UPLC) in GENOS, Glycoscience Research laboratory (Zagreb, Croatia). Additionally, to improve our understanding of the role of IgG glycosylation in the evolution of kidney function and antibody-mediated rejection in kidney transplantation, the profiles of IgG glycans have been determined with the same UPLC technique in a sub-population of 248 kidney transplant patients.

Other biomarkers available. - The cohort also has information on emerging biomarkers of cardiovascular damage, measured in a targeted way, to study their role in kidney damage associated with T2D and how these are influenced by kidney function and albuminuria. In this way, we have carried out the determination of Galectin 3 and Succinate in a sub-set of participants. **Galectin 3** (GL3) is a β -galactoside-binding lectin that has emerged as a key regulator of inflammation and fibrosis (48–51). Higher GL3 levels have been linked to an increased CV morbid-mortality risk in the general population. It has been correlated to ischemic cardiomyopathy and lower eGFR in non-diabetic cohorts (52). However, the role of its circulating levels on kidney function in T2D populations has not been fully explored (53,54). In the GenoDiabMar registry, we determined the circulating serum levels of this biomarker using ELISA techniques in a sub-set of 369 patients from the nephrology consultations, which could help to understand its relationship with renal function and its prognostic value in this population. Along the same line, circulating levels of **succinate** were also measured by fluorometric assay (EnzyChrom™ Kit) (55) in 602 participants of the cohort. The succinate is a metabolite produced by both the microbiota and the host. It is an intermediate component of the tricarboxylic acid cycle, involved in the formation and elimination of reactive oxygen species that has been linked with hypertension, ischemic heart disease, T2D and obesity (56–59). Thus, in recent years it has been postulated as a marker of high CV risk. Experimental studies suggest that its tissue accumulation and the signalling of its receptor (SUCNR1) activates the cellular response that triggers

kidney damage in diabetes and increases the release of renin (60). Nevertheless, little is known about its practical involvement in the clinic and has never been studied in populations with decrease renal function.

DNA banking. - To facilitate future genetic studies, all the participants in the registry underwent DNA extraction from the whole blood sample obtained at the baseline visit. DNA was extracted in an automated method by Qiasymphony using the Qiasymphony DSP DNA, kit for whole blood, in the MarBiobank facilities. This DNA bank will facilitate future genomic sequencing analysis projects. This cohort is postulated as ideal for conducting studies to confirm and replicate results in the search for genetic markers associated with complications of T2D in larger cohorts. Likewise, it will allow to broaden holistic evaluation analysis, based on system biology studies.

RESULTS

General characteristics

The most relevant clinical characteristics and analytical variables of the cohort are displayed in **Table 1 and Table 2**. A total of 650 participants, 61% men and 39% women, aged 69.56 ± 9.31 with a median time of diabetes of 15 [11-21] years, underwent the first visit. Of those, 356 (54.7%) had diabetic kidney disease at baseline and distribution per degree of chronic kidney disease was; G1-2 50.3%, G3 31.4%, G4 10.8% and G5 7.5%. Roughly 5 years later (Last in-person visit), 442 participants with their kidney functioning ended the follow up (Table 2). As expected, the presence of DR was significantly more frequent as glomerular filtration rate worsened and was present in 25.8% at baseline and 30.5% in the last visit. The mean body mass index (BMI) was $30.4 (\pm 5.08)$ Kg/m². Among the participants, 47.1% had a history of associated family history of T2D. 18% of the patients were active smokers, while 37.4% were ex-smokers. It should be noted that as the degree of CKD worsens, we found a significantly lower percentage of smokers. The prevalence of arterial hypertension was high, with 91.4% of the population being affected and 77.2% had dyslipidaemia. Regarding the history of previous CV events, 20.6% had a history of ischemic heart disease, with a higher prevalence peak in individuals with grade 4 CKD, 10.5% had suffered from cerebrovascular disease and 19.8% had peripheral vascular disease, both ailments again, with a higher prevalence in

grade 4 CKD. In respect of anti-hypertensive treatment: 29.8% received angiotensin-converting enzyme inhibitors (ACEI), 40.6% angiotensin receptor blockers (ARB) and 2.8% a combination of ACEI and ARB. As detailed in the tables, as glomerular filtration rates worsen, inhibitors of the renin-angiotensin system usage decreases, with a significant drop in grades 4-5. In addition, 78% of the participants received calcium channel blockers, beta-blockers, or diuretics. 72.6% used statins with a higher prevalence in grade 4 of CKD. Concerning antidiabetic drugs, 46.3% of the participants were taking oral antidiabetic drugs (OADs), 24.3% insulin, and 28.3% combined both treatments (OADs and insulin). As detailed in the tables, the use of OADs decreases significantly as the eGFR worsens, with a clear increase in the insulin usage, being the treatment of choice in 79.6% of patients with grade 5 CKD at baseline visit. Of note, the use of drugs with a demonstrated nephroprotective effect such as SGLT2i or GLP1-RA at the baseline visit (years 2012-2015) was practically anecdotal, with a clear tendency to increase their prescription on the final visit. Albeit, at the beginning of 2020, they were still far from being part of the treatment in most of these patients and, in line as other studies, the actual use of these drugs kept apart from the current clinical practice guidelines (61,62).

Longitudinal data are available for a wide range of clinical and analytical variable as well as for metabolomic and glycomic studies. We assessed the evolution of renal function in the 611 participants with functioning kidneys at the baseline visit (non-dialysis patients). The overall mean annual glomerular filtration loss was -1.2 (-1.8: -0.5 mL/min/1.73m²), being different between men and women. Men had a median eGFR higher than women at baseline (66.3 [41.8: 84.3] vs 63.4 [41.7: 86.4] mL/min/1.73m²), but the rate of loss of kidney function was significantly lower in women, losing 0.93 (0.40-1.46) less glomerular filtration units per year than men, regardless of albuminuria

Figure 1. Roughly 17% of the patients experienced rapid progression of renal function, defined as loss of ≥ 5 ml/min/1.73 m²/year (34) over the follow-up period, of those 75.2% were men and 24.7% were women.

The parameters influencing a faster progression of renal function were different between sexes. As depicted in **table 3**, the presence of peripheral vascular disease was a risk factor for women but not for men. Also, macroalbuminuria was a significant factor for men but not for women. The AUC for predicting rapid progression by albuminuria

was 0.62[0.55:0.68] with a cut-off value of 451 mg/g for men and 0.70[0.62-0.78] with a cut-off value of 18.4 mg/g for women. These findings can help to identify early clinical and analytical risk factors for worse renal evolution in a differential and more personalized way. The characteristics of the evolution of renal function and the differences found between the sexes are like those described in the literature (63–65). This observation reinforces the value of this registry as a population with renal characteristics comparable to other cohorts to be able to carry out collaborative studies. Although this registry was initially started with the objective of studying new biomarkers of kidney injury in T2D, it is a well-characterized population that has detailed information on other micro and macrovascular diabetic complications. During the follow-up period 135 patients (22.1%) endured one or more CV events (**Figure 2**), of which 33.3% fulfilled the established criteria for DKD and 18.4% did not match the DKD criteria at baseline ($p<0.001$). During the follow-up, 137 patients (22.4%) developed DR or worsening of the previous established one (**Figure 2**). There was an overall mortality of 23%, 38% due to cardiovascular causes and 16% due to cancer. Also, throughout the follow-up, 22 patients (3.6%) started renal replacement therapy and 10 were lost to follow-up (**Figure 3**).

DISCUSSION

This is a well characterized registry that gathered longitudinal micro and macrovascular complications of T2D as well as detailed clinical and analytical information. In addition, its main strengths are that includes a collection of baseline and longitudinal follow-up biological samples and covers the entire spectrum of kidney disease, including patients from grade 1 to patients on renal replacement therapy. As they are patients from medical consultations belonging to our healthcare area we have detailed and precise information about them and we can ensure the monitoring capacity. In this way, the participants of this registry are patients from the “*real world*” who sometimes may be excluded from other types of clinical trials or studies, with strict inclusion criteria. One of the limitations of the study is the generalizability of the findings, which is limited to Caucasian subjects. The results of our studies may be validated in multi-ethnic cohorts to evaluate the applicability in broader populations with T2D. We do not have urine

samples from all the participants and lack information regarding diet and lifestyle. Also, we do not have kidney histological studies in most of the patients to ensure the renal disease aetiology. Since no other reliable and non-invasive markers have been established, we cannot overcome this limitation but, to minimize misdiagnosis, medical history including ultrasonography and fundoscopy studies were reviewed by two nephrologists.

As described, we have a registry of patients from nephrology and primary care real medical out-patient consults, from which we have registered several clinical and analytical variables for 5 years. In addition, the registry includes serum and urine biobank, DNA bank, as well as data on metabolomics, glycomics and other biomarkers already analysed. Complete list of data and samples available at baseline visit, last visit and annually during follow-up are summarized in **Table 4**.

We consider that this cohort to be postulated as a great tool for scientific collaboration for studies, whether they are focused on T2D, or whether they are interested in comparing differential markers between diabetic and non-diabetic populations. Furthermore, as we have shown in other collaborative projects, the GenoDiabMar registry can meet the criteria to replicate or meta-analyse results obtained in other cohorts. It should be noted that this registry is part of The Consortium of Metabolomics Studies (COMETS) whose main objective is to create a collaborative network to identify metabolomic markers associated with different phenotypes and pathologies (66). In this way, collaboration with the GenoDiabMar project could open collaborations with other studies worldwide that are part of COMETS.

The main objective of this descriptive publication of our GenoDiabMar registry is to engage researchers in collaborative efforts to advance knowledge of the aetiology, diagnosis, treatment, and prognosis of T2D complications. In that spirit, we invite researchers including those without data of their own, to join us with scientific collaboration proposals.

Acknowledgements:

Clara Barrios is funded by grants FIS-FEDER-ISCI PI16/00620 (Ext 2021) and Strategic Plan for Research and Innovation in Health, CatSalut, PERIS STL008 (2019-2021) to

develop clinical and epidemiological studies mainly focused in diabetes and its associations with new biomarkers.

Author Contributions

Conceptualization, C.B.; methodology, A.S., S.O., A.F., M.V., J.F-N., X.M., validation, C.B. and J.P.; formal analysis, A.S., S.O., X.D., A.C-G and C.B.; investigation, A.S., E.R, E.M and C.B.; resources and funding acquisition, J.P, M.C and C.B; data curation, A.S., S.O., X.D., A.C-G and C.B.; writing—original draft preparation, A.S, S.O. and C.B.; writing—review and editing, all authors; supervision, C.B.; All authors have read and agreed to the published version of the manuscript.”

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Tables and figures legends

Table 1. General characteristic at baseline visits by grades of chronic kidney disease

Grade 1-2, eGFR>90-60 ml/min/1.73m², grade 3 eGFR; 59-30 ml/min/1.73m², grade 4 eGFR; 29-15 ml/min/1.73m² and grade 5 eGFR<15 ml/min/1.73m². CKD: Chronic kidney disease BMI: Body mass index, HBP: High blood pressure, ACEI/ARB: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers, iDPP4: Inhibitors of dipeptidyl peptidase 4, iSGLT2: Sodium glucose co-transporter inhibitors, GLP1-RA: Glucagon-like peptide-1 receptor agonists, HbA1c: glycosylated hemoglobin, LDL: low density lipoprotein, HDL: high density lipoprotein.

Table 2: General characteristics at baseline visits and at the end of follow-up visit.

BMI: Body mass index, ACEI/ARB: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers, iDPP4: Inhibitors of dipeptidyl peptidase 4, iSGLT2: Sodium glucose co-transporter inhibitors, GLP1-RA: Glucagon-like peptide-1 receptor agonists, eGFR: estimated glomerular filtration rate, HbA1c: glycosylated hemoglobin, LDL: low density lipoprotein, HDL: high density lipoprotein.

Table 3: Risk factors of having rapid progression of kidney function by sex. Multivariate logistic regression model showing the variables of risk of having a rapid decline of renal function, defined as a loss of > 5ml /min/m² of estimated glomerular filtration rate (eGFR) per year, separated by sex.

Table 4: Summary available data and samples from different visits and follow-up.

V1: First in-person visit, V2: Last in-person visit. HBP: High blood pressure, DL: dyslipidemia. HbA1c: glycosylated hemoglobin, LDL: low density lipoprotein, HDL: high density lipoprotein. NMR: nuclear magnetic resonance spectroscopy, UPLC: high performance liquid chromatography.

Figure 1: Evolution of estimated glomerular filtration rate (eGFR) per sex, adjusted by albuminuria, in the Mixed Linear Model and its graphic representation of the mean eGFR between sexes.

Figure 2: Schematic distribution of the recorded cardiovascular events (Ischemic heart disease, Peripheral vascular disease, Cerebrovascular disease) and new onset of diabetic retinopathy, throughout the follow-up period.

Figure 3: Flow-chart depicts patients' distribution during follow-up, need of renal replacement therapy (RRT), mortality and it causes.

REFERENCES

1. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Kaabi J Al. Epidemiology of Type 2 diabetes - Global burden of disease and forecasted trends. *J Epidemiol Glob Health*. 2020;10(1).
2. Einarson TR, Acs A, Ludwig C, Panton UH. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review. Vol. 21, *Value in Health*. 2018.
3. Speight J, Holmes-Truscott E, Hendrieckx C, Skovlund S, Cooke D. Assessing the impact of diabetes on quality of life: what have the past 25 years taught us? Vol. 37, *Diabetic Medicine*. 2020.
4. Preston SH, Choi D, Elo IT, Stokes A. Effect of diabetes on life expectancy in the United States by race and ethnicity. *Biodemography Soc Biol*. 2018;64(2).
5. Webster AC, Nagler E V., Morton RL, Masson P. Chronic Kidney Disease. Vol. 389, *The Lancet*. 2017.
6. Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, et al. Changes in Diabetes-Related Complications in the United States, 1990–2010. *N Engl J Med*. 2014;370(16).
7. Tancredi M, Rosengren A, Svensson A-M, Kosiborod M, Pivodic A, Gudbjörnsdóttir S, et al. Excess Mortality among Persons with Type 2 Diabetes. *N Engl J Med*. 2015;373(18).
8. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. Vol. 17, *Journal of the American Society of Nephrology*. 2006.
9. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. *Lancet*. 2012;380(9844).
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. *N Engl J Med*. 2004;351(13).
11. Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Winkelmayr WC, Nally J V. Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD. *Am J Kidney Dis*. 2017;70(2).
12. Barrios C, Pascual J, Otero S, Soler MJ, Rodríguez E, Collado S, Faura A, Mojal S, Navarro-González JF, Betriu A, Fernandez E VJ. Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. *Atherosclerosis*. 2015;242(1):37–44.
13. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: A systematic review. *JAMA - J Am Med Assoc*. 2015;313(8).

14. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. *N Engl J Med*. 2012;367(1).
15. Pasala S, Carmody JB. How to use... serum creatinine, cystatin C and GFR. *Arch Dis Child Educ Pract Ed*. 2017;102(1).
16. Stevens LA, Coresh J, Greene T, Levey AS. Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate. *N Engl J Med*. 2006;354(23).
17. Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. *Diabetes Care*. 2014;37(1).
18. Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Vol. 24, *Current Opinion in Nephrology and Hypertension*. 2015.
19. Jha JC, Jandeleit-Dahm KAM, Cooper ME. New insights into the use of biomarkers of diabetic nephropathy. Vol. 21, *Advances in Chronic Kidney Disease*. 2014.
20. Zhang Y, Zhang S, Wang G. Metabolomic biomarkers in diabetic kidney diseases - A systematic review. Vol. 29, *Journal of Diabetes and its Complications*. 2015.
21. Barrios C, Spector TD, Menni C. Blood, urine and faecal metabolite profiles in the study of adult renal disease. Vol. 589, *Archives of Biochemistry and Biophysics*. 2016.
22. Sekula P, Goek ON, Quaye L, Barrios C, Levey AS, Römisch-Margl W, et al. A metabolome-wide association study of kidney function and disease in the general population. *J Am Soc Nephrol*. 2016;27(4).
23. Barrios C, Beaumont M, Pallister T, Villar J, Goodrich JK, Clark A, et al. Gut-microbiota-metabolite axis in early renal function decline. *PLoS One*. 2015;10(8).
24. Rysz J, Gluba-Brzózka A, Franczyk B, Jablonowski Z, Ciałkowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. Vol. 18, *International Journal of Molecular Sciences*. 2017.
25. Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Vol. 61, *Diabetologia*. 2018.
26. Barrios C, Zierer J, Würtz P, Haller T, Metspalu A, Gieger C, et al. Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations. *Sci Rep*. 2018;8(1).
27. Barrios C, Zierer J, Gudelj I, Stambuk J, Ugrina I, Rodríguez E, et al. Glycosylation profile of IgG in moderate kidney dysfunction. *J Am Soc Nephrol*. 2016;27(3).
28. Dubin RF, Rhee EP. Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. *Clin J Am Soc Nephrol*. 2020;15(3).

29. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*. 2020;75(6).
30. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Vol. 41, *European Heart Journal*. 2020.
31. Nephropathies research group of the Hospital del Mar Medical Research Institute, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques). Nephrology and Renal Transplant Service of the Parc de Salut MAR. https://www.imim.es/programesrecerca/rct/es_nefropaties.html.
32. Parc de Salut Mar's biobank. Hospital del Mar Medical Research Institute, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques). https://marbiobanc.imim.es/en_index/.
33. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9).
34. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl*. 2013;3(1):1–150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.
35. Beckonert O, Keun HC, Ebbels TMD, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat Protoc*. 2007;2(11).
36. Fischer K, Kettunen J, Würtz P, Haller T, Havulinna AS, Kangas AJ, et al. Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons. *PLoS Med*. 2014;11(2).
37. Dona AC, Jiménez B, Schafer H, Humpfer E, Spraul M, Lewis MR, et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. *Anal Chem*. 2014;86(19).
38. Grinde MT, Giskeødegård GF, Andreassen T, Tessem MB, Bathen TF, Moestue SA. Biomarker Discovery Using NMR-Based Metabolomics of Tissue. In: *Methods in Molecular Biology*. 2019.
39. Silva RA, Pereira TCS, Souza AR, Ribeiro PR. ¹H NMR-based metabolite profiling for biomarker identification. Vol. 502, *Clinica Chimica Acta*. 2020.
40. Moayyeri A, Hammond CJ, Valdes AM, Spector TD. Cohort profile: Twinsuk and healthy ageing twin study. *Int J Epidemiol*. 2013;42(1).
41. Holle R, Happich M, Löwel H, Wichmann HE. KORA - A research platform for population based health research. Vol. 67, *Gesundheitswesen*. 2005.

42. Raitakari OT, Juonala M, Rönnemaa T, Keltikangas-Järvinen L, Räsänen L, Pietikäinen M, et al. Cohort profile: The cardiovascular risk in young Finns study. *Int J Epidemiol*. 2008;37(6).
43. Damelang T, Rogerson SJ, Kent SJ, Chung AW. Role of IgG3 in Infectious Diseases. Vol. 40, *Trends in Immunology*. 2019.
44. Granger V, Peyneau M, Chollet-Martin S, de Chaisemartin L. Neutrophil Extracellular Traps in Autoimmunity and Allergy: Immune Complexes at Work. Vol. 10, *Frontiers in Immunology*. 2019.
45. Castro-Dopico T, Clatworthy MR. IgG and Fcγ receptors in intestinal immunity and inflammation. Vol. 10, *Frontiers in Immunology*. 2019.
46. Lu J, Mold C, Du Clos TW, Sun PD. Pentraxins and Fc receptor-mediated immune responses. *Front Immunol*. 2018;9(NOV).
47. Wang TT. IgG Fc Glycosylation in Human Immunity. In: *Current Topics in Microbiology and Immunology*. 2019.
48. Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafina M, López B, et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation: Mechanistic insights and clinical implications. *Hypertension*. 2019;73(3).
49. Barman SA, Bordan Z, Batori R, Haigh S, Fulton DJR. Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension. In: *Advances in Experimental Medicine and Biology*. 2021.
50. Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Vol. 41, *International Journal of Molecular Medicine*. 2018.
51. Zhong X, Qian X, Chen G, Song X. The role of galectin-3 in heart failure and cardiovascular disease. Vol. 46, *Clinical and Experimental Pharmacology and Physiology*. 2019.
52. Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, de Boer I, et al. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. *Am J Kidney Dis*. 2018;72(4).
53. Hodeib H, Hagraas MM, Abdelhai D, Watany MM, Selim A, Tawfik MA, et al. Galectin-3 as a prognostic biomarker for diabetic nephropathy. *Diabetes, Metab Syndr Obes Targets Ther*. 2019;12.
54. Hussain S, Habib A, Hussain MS, Najmi AK. Potential biomarkers for early detection of diabetic kidney disease. *Diabetes Res Clin Pract*. 2020;161.
55. Institut d'Investigació Sanitària Pere Virgili, Endocrinology and Nutrition Service, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain. <https://www.iispv.cat/recerca/nutricio-i-metabolisme/>.

56. Yang L, Yu D, Mo R, Zhang J, Hua H, Hu L, et al. The succinate receptor GPR91 is involved in pressure overload-induced ventricular hypertrophy. *PLoS One*. 2016;11(1).
57. Andrienko TN, Pasdois P, Pereira GC, Ovens MJ, Halestrap AP. The role of succinate and ROS in reperfusion injury – A critical appraisal. Vol. 110, *Journal of Molecular and Cellular Cardiology*. 2017.
58. Ceperuelo-Mallafré V, Llauradó G, Keiran N, Benaiges E, Astiarraga B, Martínez L, et al. Erratum: Preoperative circulating succinate levels as a biomarker for diabetes remission after bariatric surgery (*Diabetes Care* (2019) 42 (1956–1965) DOI: 10.2337/dc19-0114). Vol. 42, *Diabetes Care*. 2019.
59. Astiarraga B, Martínez L, Ceperuelo-Mallafré V, Llauradó G, Terrón-Puig M, Rodríguez MM, et al. Impaired succinate response to a mixed meal in obesity and type 2 diabetes is normalized after metabolic surgery. *Diabetes Care*. 2020;43(10).
60. Peti-Peterdi J, Gevorgyan H, Lam L, Riquier-Brison A. Metabolic control of renin secretion. Vol. 465, *Pflugers Archiv European Journal of Physiology*. 2013.
61. Glycemic targets: Standards of medical care in diabetes-2020. *Diabetes Care*. 2020;43.
62. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. Erratum: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (*Diabetes Care*, (2020) 43, (487-493), 10.2337/dci19-0066). Vol. 43, *Diabetes Care*. 2020.
63. Ricardo AC, Yang W, Sha D, Appel LJ, Chen J, Krousel-Wood M, et al. Sex-related disparities in CKD progression. *J Am Soc Nephrol*. 2019;30(1).
64. Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. *Am J Kidney Dis*. 2016;68(6).
65. Fernandez-Fernandez B, Mahillo I, Sanchez-Rodriguez J, Carriazo S, Sanz AB, Sanchez-Niño MD, et al. Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease. *J Clin Med*. 2020;9(6).
66. CONsortium of METabolomics Studies (COMETS). National Cancer Institute, The division of cancer control and population sciences (DCCPS). <https://epi.grants.cancer.gov/comets/>.

Table 1. General characteristic at baseline visits by grades of chronic kidney disease

Grade 1-2, eGFR>90-60 ml/min/1.73m², grade 3 eGFR; 59-30 ml/min/1.73m², grade 4 eGFR; 29-15 ml/min/1.73m² and grade 5 eGFR<15 ml/min/1.73m². CKD: Chronic kidney disease BMI: Body mass index, HBP: High blood pressure, ACEI/ARB: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers, iDPP4: Inhibitors of dipeptidyl peptidase 4, iSGLT2: Sodium glucose co-transporter inhibitors, GLP1-RA: Glucagon-like peptide-1 receptor agonists, HbA1c: glycosylated hemoglobin, LDL: low density lipoprotein, HDL: high density lipoprotein.

CKD grade	1 - 2	3	4	5	p
N	327	204	70	49	<0.001
Age (years)	66.2 (8.3)	73.5 (9.03)	75 (8)	67.9 (8.9)	<0.001
Time of diabetes (years)	15 (8.2)	17.9 (8.8)	19.6 (9.7)	19.8 (8.4)	<0.001
Gender (Male:Female) %	61.8/38.2	61.6/38.2	55.7/44.3	61.3/38.8	0.812
BMI (Kg/m ²)	30.2 (5)	31 (5.2)	30.5 (4.8)	28.8 (4.9)	0.045
Smokers/former smokers %	24.8/34.5	15.2/39.2	4.3/45.7	4.1/36.7	<0.001
HBP %	69.4	98.5	95.7	100	<0.001
Antihypertensive treatment ACEI/ARB/ACEi+ARB %	32.7/39.7/3.1	35.3/45.6/2.9	11.4/41.4/5.7	14.3/49/0	<0.001
Cardiovascular events history (%)	31.5	46.1	60	48.9	<0.001
Ischemic cardiomyopathy	12.8	26.5	34.3	28.6	<0.001
Cerebrovascular disease	9.5	11.3	37.1	10.2	0.822
Peripheral vascular disease	14.7	23	12.9	22.5	0.019
Diabetic retinopathy %	17.1	27.9	34.3	63.3	<0.001
Lipid-lowering therapy (statin %)	71.8	80.9	85.7	85.7	0.002
Antidiabetic treatment %					
Oral agents/Insulin/combined	59.3/6.1/33.9	43.1/28.4/26.9	7.3/58.6/20	8.1/79.6/6.1	<0.001
iDPP4/iSGLT2/GLP1-AR	7.6/0.3/0.9	1.9/0.5/0.5	1.4/0/0	0/0/0	0.808
eGFR (mL/min/1.73m ²)	82.2 [24.1]	42.8 [13.2]	23.5 [19.6]	9.14 (3.75)	<0.001
Albuminuria/Cr (mg/g)	9.5 [53.3]	85.8 [434]	465 [1574.7]	1158 [3210.8]	<0.001
HbA1C (%)	7.7 (1.3)	7.8 (1.3)	7.6 (1.2)	7 (1.1)	0.004
Cholesterol (mg/dL)					
Total	177.8 (36.5)	168 (34)	169 (41.5)	146.2 (40.3)	<0.001
LDL	101.3 (30.9)	92.4 (27.4)	98 (35.6)	72.3 (31.7)	<0.001
HDL	47.7 (12.5)	46.2 (13.2)	46.6 (14.3)	46.5 (15.1)	0.665
Triglycerides (mg/dL)	129 [91.7]	144 [86]	141 [93]	125 [60]	0.072
Uric acid (mg/dL)	5.5 (1.3)	6.7 (1.7)	7.2 (2)	5.3 (1.7)	<0.001
Hemoglobin (mg/dL)	13.6 [2.1]	12.6 [1.88]	11.5 [1.45]	12.1 [2]	<0.001

Table 2: General characteristics at baseline visits and at the end of follow-up visit. BMI: Body mass index, ACEI/ARB: Aangiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers, iDPP4: Inhibitors of dipeptidyl peptidase 4, iSGLT2: Sodium glucose co-transporter inhibitors, GLP1-RA: Glucagon-like peptide-1 receptor agonists, eGFR: estimated glomerular filtration rate, HbA1c: glycosylated hemoglobin, LDL: low density lipoprotein, HDL: high density lipoprotein.

	First Visit 2012-2015	Last Visit 2017-2020
N	650	442
Age (years)	69.6 (9.3)	73 (8.9)
Sex (male/female.%)	61.1/38.9	61.5/38.8
BMI (Kg/m²)	30.4 (5.08)	29.75 (5.3)
Time of diabetes (years)	16.8 (8.9)	20.05 (8.5)
Family history of diabetes (%)	47.1	53.1
Cardiovascular risk factors history		
Smokers/former smoker (%)	18/37.4	15.8/41.4
High Blood Pressure (%)	91.4	90.9
Dyslipidemia (%)	77.2	73
Cardiovascular events history (%)	40.5	41.17
Myocardial infarction (%)	20.6	21.3
Cerebrovascular disease (%)	10.5	14.3
Peripheral vascular disease (%)	19.8	20.4
Diabetic retinopathy (%)	25.8	30.5
Current medication		
Antihypertensive treatment		
ACEI/ARB/ACEI+ARB (%)	29.8/40.6/2.8	31/37.8/2.3
Others (Calcium-antagonist, β-blocker, diuretics) (%)	78	80.8
Lipid-lowering therapy (%)		
Statins	72.6	68.1
Fibrates	10.1	6.8
Other	3.4	7.8
Antidiabetic treatment		
Oral agents only (%)	46.3	41.2
DPP4i/SGLT2i/GLP-1a (%)	6.1/0.3/0.6	21/5.9/4.3
Insulin only (%)	24.3	21
Oral agents + insulin (%)	28.3	34.6
Diet (%)	1.1	1.1
Serum Creatinine (mg/dl)	1.12 [0.81]	1.11 [0.78]
eGFR (ml/min/1.73mt²)	60.4 [46.5]	54.5 [48.6]
Urinary albumin/creatinine (mg/gr)	34.1 [221.5]	32.6 [212]
Hemoglobin (gr/dl).	13.2 (4.9)	13.4 (5.7)
HbA1c (%)	7.6 [1.75]	7.2 [1.67]
Uric acid (mg/dl)	6.25 (1.71)	6.05 (1.8)
Total Cholesterol (mg/dl)	173.3 (37.5)	166.7 (42.5)
LDL-cholesterol (mg/dl)	97.7 (31.4)	95.4 (32.7)
HDL-cholesterol (mg/dl)	47.1 (37.1)	47.6 (15.1)
Triglycerides (mg/dl)	153.9 (79.8)	162.8 (89.9)

Table 3: Risk factors of having rapid progression of kidney function by sex. Multivariate logistic regression model showing the variables of risk of having a rapid decline of renal function, defined as a loss of > 5ml /min/m² of estimated glomerular filtration rate (eGFR) per year, separated by sex.

	Men		Women	
	<i>OR (IC95%)</i>	<i>p</i>	<i>OR (IC95%)</i>	<i>p</i>
Age	1.01 (0.98:1.04)	0.62	1.02 (0.97:1.08)	0.48
Diabetic retinopathy	1.18 (0.61:2.23)	0.61	0.99 (0.25:3.33)	0.98
Time of DM2	1.02 (0.99:1.06)	0.18	0.97 (0.91:1.03)	0.42
BMI	1.03 (0.96:1.10)	0.45	0.97 (0.89:1.05)	0.47
Ischemic cardiopathy	1.02(0.53:1.88)	0.94	1.16(0.31:3.39)	0.80
Periph. Vascular disease	0.79 (0.39:1.53)	0.49	3.32 (1.10:9.57)	0.02
Stoke	1.83(0.85:3.74)	0.12	1.82(0.38:6.21)	0.41
Albuminuria>300mg/g	2.40 (1.29:4.44)	0.005	0.99(0.91:3.73)	0.99
HbA1c	0.89 (0.71:1.11)	0.32	1.14 (0.80:1.59)	0.43
Smoker	1.03 (0.46:2.30)	0.94	1.15 (0.21:4.97)	0.86
former smoker	0.72 (0.37:1.46)	0.35	0.29 (0.02:1.62)	0.25

Table 4: Summary available data and samples from different visits and follow-up.

V1: First in-person visit, V2: Last in-person visit. HBP: High blood pressure, DL: dyslipidemia. HbA1c: glycosylated hemoglobin, LDL: low density lipoprotein, HDL: high density lipoprotein. NMR: nuclear magnetic resonance spectroscopy, UPLC: high performance liquid chromatography.

	V1. First Visit 2012-2015	Follow-up (annually)	V2. Last Visit 2017-2020
Questionnaires			
Demographics	✓		
Time of diabetes	✓		✓
Family history of diabetes	✓		
Cardiovascular risk factors (Smoke, HBP, DL)	✓	✓	✓
Cardiovascular events history	✓	✓	✓
Current medication (anti-hypertensive, lipid-lowering, anti-diabetics treatments)	✓	✓	✓
Renal replacement therapy		✓	✓
Mortality		✓	✓
Clinical assessments			
Anthropometrics (BMI)	✓		✓
Blood pressure	✓		✓
Fundoscopy	✓		✓
Abdominal ultrasound	✓		
Laboratory analysis			
Biochemical profile (creatinine, urea, uric acid)	✓	✓	✓
Hemogram	✓		✓
Lipid profile (total cholesterol, LDL, HDL-cholesterol, triglycerides)	✓		✓
Albuminuria	✓	✓	✓
HbA1c	✓	✓	✓
Special test			
Metabolomic profiles (NMR)	✓		✓
IgG glycans profiles (UPLC)	✓		✓
Serum Galectin 3 (ELISA)	✓		✓
Serum Succinate (fluorometric)	✓		✓
Available samples			
DNA bank and whole blood sample	✓		✓
Serum samples	✓		✓
Urine samples	✓		✓

Figure 1: Evolution of estimated glomerular filtration rate (eGFR) per sex, adjusted by albuminuria, in the Mixed Linear Model and its graphic representation of the mean eGFR between sexes.

eGFR	Coeff	IC (95%)	p
Time	-2.33	(-2.66:-2.01)	<0.001
Albuminuria	-0.02	(-0.02:-0.02)	<0.001
Time*Gender	0.93	(0.40:1.46)	0.001

Figure 2: Schematic distribution of the recorded cardiovascular events (Ischemic heart disease, Peripheral vascular disease, Cerebrovascular disease) and new onset of diabetic retinopathy, throughout the follow-up period.

Figure 3: Flow-chart depicts patients' distribution during follow-up, need of renal replacement therapy (RRT), mortality and its causes.